(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 31.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Omniab's revenue in 2025 is $23,027,000.On average, 5 Wall Street analysts forecast OABI's revenue for 2025 to be $2,640,041,042, with the lowest OABI revenue forecast at $2,576,727,174, and the highest OABI revenue forecast at $2,758,325,089. On average, 5 Wall Street analysts forecast OABI's revenue for 2026 to be $4,075,155,376, with the lowest OABI revenue forecast at $2,834,399,891, and the highest OABI revenue forecast at $5,428,305,247.
In 2027, OABI is forecast to generate $6,580,470,397 in revenue, with the lowest revenue forecast at $3,546,067,397 and the highest revenue forecast at $9,492,172,104.